The company will continue with talks to sell 2,000 patients’ data to biotech companies to further research into a vaccine it has been developing since 2010. The announcement comes in the wake of the company being awarded a second U.S. patent for Favld, a vaccine to treat lymphoma and other cancers, in addition to patents in Australia, Mexico and South Korea, according to CNN MarketWired.
MMRGlobal also owns health IT patents and personal health records in 12 countries, including the U.S. Favld is the company’s first clinical trial series, into which it has invested more than $100 million, according to CNN MarketWired.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.